AOD-9604 vs Cagrilintide

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

AOD-9604 is a synthetic fragment of the human growth hormone molecule, corresponding to amino acids 176–191 of the C-terminus. It is researched specifically for its lipolytic properties and is considered a lower-risk alternative to full growth hormone analogues for body composition research, given its apparent lack of effect on insulin sensitivity or IGF-1 levels.

Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination

A once-weekly long-acting amylin analogue in late-stage development. Showing impressive weight loss (~15%) in trials, especially when combined with semaglutide (CagriSema).